Trifarotene

DRUG2 trials

Sponsors

Galderma R&D

Conditions

Acne Vulgaris

Phase 3

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

CompletedNCT03915860

Galderma R&DAcne Vulgaris

Start: 2019-03-27End: 2019-12-23Updated: 2021-12-15

A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris

Active, not recruitingNCT07186413

Galderma R&DAcne Vulgaris

Start: 2025-09-23End: 2026-12-31Target: 561Updated: 2026-08-24